Roche launched its Axelios 1 next-generation sequencing platform to compete directly with Illumina’s installed base, aiming to address bottlenecks around accuracy, speed, flexibility, scalability, and cost efficiency. The company is shipping the system commercially with an initial focus on North America, Europe, and Asia-Pacific as sequencing customers evaluate switching or expanding platforms.